NASDAQ$TELA
TELA Bio Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
TELA Bio's third quarter revenue reached a historic high, driven by strong product demand and normalized growth across the OviTex portfolio, while the company focused on commercial leadership and operating leverage.
TELA Bio reported a 26% increase in revenue to $19 million for the third quarter of 2024, marking a historic high. Gross profit was $12.9 million, or 68% of revenue. The company experienced a net loss of $10.4 million, and held $17.3 million in cash and cash equivalents as of September 30, 2024.
- Third quarter revenue reached a historic high of $19 million, reflecting strong product demand.
- Revenue increased by 26% compared to the same period in 2023, driven by increased unit sales and international growth.
- Gross profit was $12.9 million, representing 68% of revenue.
- The company is focused on commercial leadership and demonstrating increased operating leverage.
Headline financials
Revenue & EPS history
TELA Bio · Revenue · Quarterly
$19M
Forward guidance
TELA Bio reiterates its 2024 revenue guidance and anticipates reduced operating expenses in 2025 due to recently implemented operational efficiency improvements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-2.5%
Avg return
Earnings day
-3.7%
Avg return
5 days after
+3.7%
Avg return
30 days after
42%
11 / 26 earnings
Positive
+20.2%
Q1 2024
Best reaction
-37.2%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.3% | -18.6% | — | |
| Q4 2025 | +1.7% | -25.8% | -12.0% | |
| Q3 2025 | -9.3% | -2.7% | +3.6% | |
| Q1 2025 | +7.2% | -0.1% | +90.7% | |
| Q4 2024 | -37.2% | -44.9% | -59.1% | |
| Q3 2024 | +2.0% | +3.0% | -1.7% | |
| Q2 2024 | -23.9% | -23.4% | -35.0% | |
| Q1 2024 | +20.2% | +21.2% | +16.7% | |
| Q4 2023 | +4.0% | +0.9% | -13.8% | |
| Q3 2023 | -20.3% | -21.7% | -4.5% | |
| Q2 2023 | -4.8% | -1.2% | -2.8% | |
| Q1 2023 | -3.6% | -4.8% | +11.2% | |
| Q4 2022 | -5.5% | -3.7% | -11.3% | |
| Q3 2022 | +13.8% | +11.2% | +44.7% | |
| Q2 2022 | -6.5% | +5.5% | +0.9% | |
| Q1 2022 | -5.7% | -7.0% | -31.4% | |
| Q4 2021 | -4.8% | -4.8% | -20.4% | |
| Q3 2021 | -3.8% | -3.7% | -1.7% | |
| Q2 2021 | +5.0% | +4.4% | -8.3% | |
| Q1 2021 | +3.2% | +11.5% | +5.9% | |
| Q4 2020 | -6.6% | +0.9% | -1.8% | |
| Q3 2020 | -3.5% | -0.8% | -3.6% | |
| Q2 2020 | +5.4% | +4.1% | +20.7% | |
| Q1 2020 | -2.4% | -3.6% | +38.6% | |
| Q4 2019 | +0.6% | -0.4% | +34.0% | |
| Q3 2019 | +13.9% | +8.8% | +32.6% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro